Actively Recruiting
Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer
Led by University Hospital, Ghent · Updated on 2025-01-15
156
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Ghent
Lead Sponsor
K
Kom Op Tegen Kanker
Collaborating Sponsor
AI-Summary
What this Trial Is About
Evaluate the impact of 18F-FDG-PET-CT on the staging of patients with muscle invasive bladder cancer. Based on the results of 2 18F-FDG-PET-CT's patients are stratified in non-metastatic, oligometastatic and polymetastatic bladder cancer patients and the treatment is adapted accordingly to improve overall survival.
CONDITIONS
Official Title
Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histopathology-proven muscle-invasive bladder cancer on TURb or stage 3 on conventional imaging treated with radical treatment
- T1-4 N0-3 M0 muscle-invasive bladder cancer on conventional thoracic CT and abdominopelvic CT/MRI
- Age greater than 18 years
- WHO performance status 0-2
- Willingness to undergo 18F-FDG-PET-CT scanning
- Willingness to undergo metastasis-directed therapy or immunotherapy if diagnosed with oligometastatic or polymetastatic disease
- Ability to provide signed informed consent according to ICH/GCP and local regulations
You will not qualify if you...
- Presence of distant metastasis on conventional imaging (thoracic CT and abdominopelvic CT/MRI)
- Refusal or contraindications to 18F-FDG-PET-CT
- Refusal of metastasis-directed therapy or immunotherapy
- Prior radiotherapy preventing metastasis-directed therapy
- Contraindications to radiotherapy including active inflammatory bowel disease
- Contraindications to immunotherapy
- Other primary tumor diagnosed less than 5 years ago requiring treatment except non-metastatic prostate cancer or non-melanoma skin cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ghent University Hospital
Ghent, Belgium, 9000
Actively Recruiting
Research Team
V
Valerie Fonteyne, MD; PhD
CONTACT
F
Flor Verghote, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here